Inactive Instrument

Press Releases Coeptis Therapeutics, Inc. OTC Markets

Equities

COEP

US19207C1045

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award	Apr. 03	AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award	Apr. 02	PR
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	Feb. 27	AQ
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	Feb. 07	PR
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024	Jan. 04	PR
Coeptis Therapeutics to Present at the Emerging Growth Conference	Dec. 04	PR
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023	23-10-31	PR
Coeptis Therapeutics Announces $2 Million Private Placement	23-10-24	PR
Coeptis Therapeutics : Private Placement - Form 8-K	23-10-13	PU
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	23-10-11	PR
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies	23-10-09	PR
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting	23-10-04	PR
Coeptis Therapeutics to Present at the 2023 Cell and Gene Meeting on the Mesa	23-09-28	AQ
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa	23-09-27	PR
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection	23-09-14	PR
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington s Cancer Research Endowment	23-09-12	AQ
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment	23-09-11	PR
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer	23-08-30	PR
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics	23-08-17	PR
Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic	23-08-01	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Coeptis Therapeutics, Inc. OTC Markets

Equities

COEP

US19207C1045

Press Releases

Filters